Leap Therapeutics Inc

NASDAQ LPTX

Data sourced from iex and EODHD
Download Data

Leap Therapeutics Inc Income Statement 2013 - 2024

This table shows the Income Statement for Leap Therapeutics Inc going from 2013 until 2024. The income statement, also known as the profit and loss statement, is a financial statement that provides a summary of a company's revenues, expenses, and net income over a specific period (such as a quarter or a year). It shows the company's ability to generate revenue, manage expenses, and ultimately determine its profitability.
Income Statement Trend Unit 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-06-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-12-31 2013-09-30 2013-06-30 2013-03-31
Revenue
M 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - 0 - 0 0 - - - 0
Cost of Revenue
M 0 0 0 0 0 0 - - - 0 - - - - - - - - - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - 0 - 0 0 - - - 0
Gross Profit
M 0 1 0 0 0 0 - - - 0 0 0 0 0 0 0 0 - - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - 0 - 0 0 - - - 0
Operating Expenses
M 15 15 15 15 43 14 - - - 10 13 10 10 8 8 8 7 - - - - 9 9 7 6 7 9 7 10 8 7 7 5 2 - - - 8 - 4 3 - - - 2
Selling, General, and Administrative Expenses (SG&A)
M 4 3 3 4 4 3 3 3 3 3 2 3 3 2 3 3 2 3 2 2 2 2 2 3 2 2 2 2 4 1 1 1 1 1 2 2 2 1 - 1 1 1 3 1 0
Research and Development (R&D) Expenses
M 11 12 12 11 39 11 12 14 8 8 10 7 7 5 5 5 5 6 6 6 7 8 6 4 4 4 7 5 6 7 6 6 4 1 4 5 5 6 4 3 3 3 2 2 2
Other Operating Expenses
M 0 1 0 0 0 0 - - - 0 0 0 0 0 0 0 0 - - - - -1 0 0 1 0 0 0 0 0 0 0 0 0 - - - 1 - 0 0 - - - 0
Costs and Expenses
M 15 15 15 14 42 13 - - - 11 - - - - - - - - - - - 9 8 7 6 7 9 7 10 8 7 7 5 2 - - - 7 - 4 3 - - - 2
Operating Income
M -15 -15 -15 -15 -43 -14 -15 -17 -11 -10 -12 -10 -9 -7 -8 -7 -6 -8 -8 -8 -9 -9 -9 -7 -6 -7 -9 -7 -10 -8 -7 -7 -5 -2 -6 -7 -7 -8 -6 -4 -3 -4 -5 -2 -2
Interest Expense
M - 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 - - - 0 - 0 0 - - - 0
Non-operating Income/Expense
M 1 2 1 0 1 2 0 0 0 0 0 0 0 1 0 1 -1 0 0 0 11 11 2 -1 -5 0 2 0 1 3 0 0 0 0 0 0 0 0 -4 0 0 0 -5 0 0
EBT
M -14 -12 -14 -13 -42 -12 -15 -17 -10 -11 -11 -10 -9 -7 -7 -7 -7 -8 -8 -8 2 2 -7 -7 -11 -7 -7 -7 -9 -6 -7 -7 -5 -2 -6 -7 -7 -8 -10 -4 -3 -4 -10 -2 -2
Income Tax Provision
M 0 1 0 - -1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 3 0 0 0 0 0 0 0 0 - 0 0 0 0 0 0
Income after Tax
M -14 -13 -14 - -41 -12 -16 -18 -10 -11 -11 -10 -9 -7 -7 -7 -7 -8 -8 -9 1 1 -7 -7 -11 -7 -7 -7 -10 -9 -8 -8 -5 -2 -6 -7 -7 -8 - -4 -3 -4 -10 -2 -1
Non-Controlling Interest
M - - - 0 -1 0 0 -1 0 0 0 0 0 0 0 0 10 0 0 0 0 0 0 0 -1 0 -1 0 0 0 0 0 0 0 - - - 0 - 0 0 - - - 0
Net Income
M - - - -13 -42 -12 -15 -17 -10 -11 -11 -10 -9 -7 -7 -7 -17 -8 -8 -8 -9 1 -7 -7 -11 -44 -7 -7 -10 -26 0 0 0 -12 - - - -8 - 3 -3 - - - -2
Shares (Basic, Weighted)
M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Shares (Diluted, Weighted)
R 27,014,100.00 26,987,182.00 26,987,182.00 14,710,375.00 12,934,427.00 11,323,909.00 11,323,909.00 11,324,893.00 11,324,893.00 11,310,780.00 7,821,877.00 7,638,952.00 7,637,856.00 7,637,616.00 7,632,164.00 5,244,259.00 3,163,221.00 2,419,487.00 2,392,319.00 2,290,602.00 1,470,315.00 14,703,159.00 1,521,171.00 1,469,189.00 1,244,942.00 1,090,171.00 939,592.00 939,208.00 694,562.00 939,241.00 6,945,623.00 17,080,652.00 1,708,065.00 1,705,775.00 1,824,892.00 1,852,881.00 1,816,579.00 1,626,246.00 1,430,688.00 1,617,729.00 744,404.00 744,404.00 744,404.00 744,404.00 744,404.00
EBITDA
M -15 -15 -15 -13 -42 -13 -14 -16 -11 -11 -11 -9 -9 -8 -7 -7 -6 -8 -8 -8 -9 -9 -8 -6 -6 -6 -9 -7 -10 -5 -7 -7 -5 -1 -6 -6 -7 -8 -5 -4 -3 -4 -5 -2 -2
Depreciation and Amortization
M 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - 0 0 0 0 0 0 0 0 0 0 0 0
EBIT
M -15 -15 -15 -13 -43 -14 -15 -17 -11 -11 -11 -9 -9 -7 -7 -7 -6 -8 -8 -8 -9 -9 -8 -6 -6 -7 -9 -7 -10 -5 -7 -7 0 -2 -6 -7 -7 -8 -6 -4 -3 -4 -5 -2 -2
Income from Discontinued Operations
M - - - - - - - - - - - - - - - - - - - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - 0 - 0 0 - - - -
Tax Rate (Effective)
% 0.04 -5.33 -1.45 - 2.06 -1.23 -5.35 -4.31 2.26 0.22 -0.08 -1.09 0.96 0.03 -0.24 -0.20 -0.17 0.04 -0.06 -2.07 1.33 1.33 -0.06 -0.11 -0.06 2.33 0.00 0.71 -1.29 -60.15 -5.25 -3.05 0.00 -9.19 -1.13 -0.59 -0.70 0.62 - -0.87 -1.19 -1.31 -0.48 -2.16 22.44
Earnings Per Share (EPS), Basic
M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Earnings Per Share (EPS), Diluted
M - - - 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 - - - 0 - 0 0 - - - 0
Gross Profit Margin
% - 82.65 - - - - - - - 0.10 100.00 100.00 100.00 100.00 100.00 100.00 100.00 - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Operating Income Margin
% - -2,337.54 - - - - - - - -2,796.80 -3,237.33 -2,566.93 -2,445.87 -1,907.73 -2,002.13 -1,998.93 -1,701.60 - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Net Income Margin
% - - - - - - - - - -2,876.80 -2,970.40 -2,540.27 -2,435.73 -1,789.33 -1,881.87 -1,737.60 -4,614.67 - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EBITDA Ratio
% - -2,320.19 - - - - - - - -2,890.93 -2,896.80 -2,501.60 -2,426.40 -2,084.00 -1,914.13 -1,950.40 -1,607.20 - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EBIT Ratio
% - -2,337.54 - - - - - - - -2,893.07 -2,898.67 -2,478.13 -2,453.60 -1,977.87 -1,940.53 -1,985.60 -1,660.80 - - - - - - - - - - - - - - - - - - - - - - - - - - - -
EBT Ratio
% - -1,966.09 - - - - - - - -2,883.20 -2,970.40 -2,540.27 -2,435.73 -1,789.87 -1,881.87 -1,737.60 -1,928.27 - - - - - - - - - - - - - - - - - - - - - - - - - - - -

StockViz Staff

September 16, 2024

Any question? Send us an email